Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus.

Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, Brock W, De la Cruz Cabrera O, Guda K, Barnholtz-Sloan JS, Iyer PG, Canto MI, Wang JS, Shaheen NJ, Thota PN, Willis JE, Chak A, Markowitz SD.

Sci Transl Med. 2018 Jan 17;10(424). pii: eaao5848. doi: 10.1126/scitranslmed.aao5848.

2.

Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer.

Luo Y, Wong CJ, Kaz AM, Dzieciatkowski S, Carter KT, Morris SM, Wang J, Willis JE, Makar KW, Ulrich CM, Lutterbaugh JD, Shrubsole MJ, Zheng W, Markowitz SD, Grady WM.

Gastroenterology. 2014 Aug;147(2):418-29.e8. doi: 10.1053/j.gastro.2014.04.039. Epub 2014 Apr 30.

3.

NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer.

Luo Y, Kaz AM, Kanngurn S, Welsch P, Morris SM, Wang J, Lutterbaugh JD, Markowitz SD, Grady WM.

PLoS Genet. 2013;9(7):e1003552. doi: 10.1371/journal.pgen.1003552. Epub 2013 Jul 11.

4.

Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility.

Thompson CL, Fink SP, Lutterbaugh JD, Elston RC, Veigl ML, Markowitz SD, Li L.

PLoS One. 2013 May 22;8(5):e64122. doi: 10.1371/journal.pone.0064122. Print 2013.

5.

PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer.

Brunschwig EB, Wilson K, Mack D, Dawson D, Lawrence E, Willson JK, Lu S, Nosrati A, Rerko RM, Swinler S, Beard L, Lutterbaugh JD, Willis J, Platzer P, Markowitz S.

Cancer Res. 2003 Apr 1;63(7):1568-75.

6.

Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer.

Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD.

Cancer Res. 2001 Feb 1;61(3):900-2.

7.

Transforming growth factor-beta-induced growth inhibition in a Smad4 mutant colon adenoma cell line.

Fink SP, Swinler SE, Lutterbaugh JD, Massagué J, Thiagalingam S, Kinzler KW, Vogelstein B, Willson JK, Markowitz S.

Cancer Res. 2001 Jan 1;61(1):256-60.

8.

Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers.

Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, Kinzler KW, Vogelstein B, Willson JK, Markowitz S.

Cancer Res. 1999 Jan 15;59(2):320-4.

9.

Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.

Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702.

10.

Increased transversions in a novel mutator colon cancer cell line.

Eshleman JR, Donover PS, Littman SJ, Swinler SE, Li GM, Lutterbaugh JD, Willson JK, Modrich P, Sedwick WD, Markowitz SD, Veigl ML.

Oncogene. 1998 Mar 5;16(9):1125-30.

11.

Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability.

Eshleman JR, Markowitz SD, Donover PS, Lang EZ, Lutterbaugh JD, Li GM, Longley M, Modrich P, Veigl ML, Sedwick WD.

Oncogene. 1996 Apr 4;12(7):1425-32.

PMID:
8622858

Supplemental Content

Loading ...
Support Center